glp-1 drugs fda approved medicare part d coverage 2025 Recent Trends in Use and Spending in Fmr. FDA Commissioner weighs in

Very few include older adults at high risk

95 Lixisenatide is a short-acting GLP-1RA agent, 96,97 and once-daily lixisenatide can improve patient compliance to a certain extent and reduce the occurrence of hypoglycemia

Unlike generic drugs, which are FDA-approved products brought to market after patents expire, compounded meds are meant to be substitutes offered for specific purposes, like drug shortages

Finally, TRANSCEND-T2D-3 (NCT06297603) will compare retatrutide to placebo over 14 months, in people with inadequately controlled T2D and moderate-or-severe renal impairment on basal insulin

Additionally, evaluating how these therapies interact with current antidiabetic treatments and determining their suitability for combination therapies may further enhance their clinical value